Hikma Pharmaceuticals PLC header image

Hikma Pharmaceuticals PLC

HIK

Equity

ISIN GB00B0LCW083 / Valor 2324471

LSE London Stock Exchange, SETS (2026-11-06)
GBP 16.50-2.77%

Hikma Pharmaceuticals PLC
UMushroom community rating:

star star star star star
3.14 3 votes No rating yet
NegativeNeutralPositive

About company

Hikma Pharmaceuticals PLC is a London‑listed pharmaceutical company, founded in Jordan and headquartered in London, that develops, manufactures and commercialises a broad range of branded and generic medicines across the United States, the Middle East & North Africa and Europe. Its core operations cover three main areas—injectable medicines (including sterile hospital injectables), generic oral medicines and branded generics for regional markets—supplied through its own manufacturing sites and commercial networks to hospitals, wholesalers and retail pharmacies. The company combines in‑house development and manufacturing with licensing and partnerships to bring off‑patent and complex generic products to market, with a particular emphasis on injectable and hospital-use therapies.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (25.10.2026):

Hikma Pharmaceuticals PLC — results for the year ended 31 December 2025 (full‑year 2025; this is an annual report rather than a quarterly release). The Group delivered core revenue growth and modest core profit growth in line with guidance, while reported operating profit and operating cash flow were hit by one‑off legal settlements; the Board raised the dividend, announced a $250m share buyback and implemented a series of immediate leadership changes to sharpen execution.

Top-line and profit (headline)

Core revenue $3,349m (up 6% constant currency; reported revenue up 7%). Core operating profit $741m (up 3%) and core EBITDA $853m (up 4%). Reported operating profit $542m (down 11%) mainly due to a legal settlement related to sodium oxybate.

Earnings, cash and dividend

Core profit attributable to shareholders $503m (up 2%); reported profit $402m (up 12%). Core basic EPS 228 cents (2024: 224), reported basic EPS 182 cents (2024: 162). Operating cash flow $436m (2024: $564m); excluding $186m of one‑off legal settlements cash flow rose ~10%. Total dividend increased 5% to 84 cents per share.

Balance sheet and capital returns

Net debt $1,387m; net debt to core EBITDA 1.6x (31 Dec 2024: 1.4x). Group upgraded to BBB (stable) by S&P and Fitch. Board announced a share buyback programme of up to $250m to be executed in 2026.

2026 guidance

Group revenue growth guidance: 2%–4% (constant currency). Group core operating profit guidance: $720m–$770m. Segment outlook: Injectables revenue low single digits and margin 27%–28%; Branded revenue 6%–8% and ~25% margin; Hikma Rx broadly flat revenue and margin close to 20%.

Segment performance — Injectables

Injectables core revenue $1,423m (up 7%); core operating profit down 6% with core margin 31.0% (2024: 35.3%). Margin pressure from geographic/product mix, higher use of third‑party manufacturing and inventory provisions; investment planned to strengthen the business.

Segment performance — Branded

Branded core revenue $849m (up 10%); core operating profit up 19% with margin 26.4% (improved mix and strong launches in oncology and diabetes across MENA).

Segment performance — Hikma Rx

Hikma Rx core revenue $1,037m (flat); core operating profit up 5% with margin 17.3% as higher‑complex product demand and lower S&M offset price erosion and inventory provisions.

One‑offs and expenditure

Reported operating profit and cashflow were materially affected by a legal settlement (total one‑off items c.$186m; $111m in restricted cash at 31 Dec 2025, paid Jan 2026). R&D spend $151m (4.5% of core revenue) with aspiration to reach 5%–6% of revenue; capex $197m (guidance $190m–$210m for 2026).

Strategy, launches and pipeline

Strategic progress included 84 launches in 2025, US launch of Tyzavan® (ready‑to‑use vancomycin bag), first US biosimilar (ustekinumab) approval and 118 injectable projects in the pipeline (15 ready‑to‑use formulations). Bedford commercial production expected from 2028.

Leadership changes

Immediate Board/management moves: Said Darwazah to focus solely on CEO and step down as Executive Chair; Victoria Hull appointed Chair; two Deputy CEO roles created (MENA; North America & Europe); CFO search initiated and Areb Kurdi named Acting CFO; organisational changes to accelerate execution.

Summarized from source with an LLMView Source

Key figures

8.41%1Y
-8.38%3Y
-31.4%5Y

Performance

36.1%1Y
28.3%3Y
28.7%5Y

Volatility

Market cap

4677 M

Market cap (USD)

Daily traded volume (Shares)

764,834

Daily traded volume (Shares)

1 day high/low

19.9 / 19.68

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

3.14

3 votes
Performance:
starstarstarstarstar
3.14
Innovation:
starstarstarstarstar
3.14
Society:
starstarstarstarstar
3.14
Nature:
starstarstarstarstar
3.14
Moska Ahmadzai
UK, 26 Oct 2025
star star star star star
Has not generated positive returns recently
Brooklyn Fu
UK, 20 Oct 2025
star star star star star
secure
Francesco Cuviello
Switzerland, 30 Mar 2025
star star star star star
Interessante Anlage

EQUITIES OF THE SAME SECTOR

Lupin Limited
Lupin Limited Lupin Limited Valor: 11598960
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.13%INR 1,990.00
ImmunityBio Inc
ImmunityBio Inc ImmunityBio Inc Valor: 110468647
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
7.80%USD 8.63
Astrana Health Inc
Astrana Health Inc Astrana Health Inc Valor: 28041888
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-11.56%USD 34.50
2invest AG
2invest AG 2invest AG Valor: 110098281
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.25%EUR 6.32
Terveystalo Oyj
Terveystalo Oyj Terveystalo Oyj Valor: 37893402
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.81%EUR 6.23
Siemens Healthineers AG
Siemens Healthineers AG Siemens Healthineers AG Valor: 40652181
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.76%EUR 44.66
Beiersdorf AG
Beiersdorf AG Beiersdorf AG Valor: 324660
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.70%EUR 85.26
BridgeBio Pharma Inc
BridgeBio Pharma Inc BridgeBio Pharma Inc Valor: 48204826
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.03%USD 74.29
Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA Fresenius SE & Co. KGaA Valor: 332902
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.18%EUR 52.48
Allogene Therapeutics Inc
Allogene Therapeutics Inc Allogene Therapeutics Inc Valor: 43756548
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-4.59%USD 1.04